Prompt Action
Assured Control

Fixed Dose Combination therapy:
MONTEL ®: LEVOCETIRIZINE 5MG + MONTELUKAST 10MG
MONTEL ® DT: LEVOCETIRIZINE 4MG + MONTELUKAST 2.5MG

Mode of Action

Molecules

i. LEVOCETIRIZINE

A selective, second generation H1 histamine antagonist.
Prevents smooth muscle contraction, increased permeability of vascular endothelium, histidine uptake in basophils, stimulation of cough receptors, and stimulation of flare responses in the nervous system.

Goes beyond merely H1 antagonism:
  • To inhibits IL-6, IL-8 and GM-CSF production.
  • To reduce eosinophils and some activated T lymphocytes that contribute to inflammatory tissue damage.

  • Molecules

    ii. MONTELUKAST

    Binds with high affinity and selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor , CysLT1, in airways.
    This prevents airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.

  • Reduces peripheral blood eosinophils.

  • INDICATIONS AND POSOLOGY

    Adults (MONTEL ®) and children (MONTEL ® DT): One tablet once daily for treatment of

    Request A Sample

    MONTEL ® UNIQUE CLINICAL FEATURES

    • Favorable safety profile (Pregnancy category B) and well tolerated.
    • Montelukast, an alternative anti-inflammatory medications in the management of chronic asthma and exercise-induced bronchospasm (EIB)
    • Levocetrizine, active R enantiomer of cetirizine that exhibits two fold increase in affinity for H1 receptors over cetrizine.
    • Levocetrizine, potent antihistamine (than Loratidine, ebastine, fexofenadine and mizolastine).
    • Based on adequate and wellcontrolled clinicalstudies Rupatidine is not superior or does not work any better than Levocetrizine.
    • Efficacious and improves quality of life than individual drugs given alone.